Abstract
Background
Estrogen signalling is transmitted via various receptors and multiple intracellular signalling pathways. Estrogen receptor alpha (ERα)-mediated transcription of target genes has been demonstrated to be closely linked to human papilloma virus (HPV)-induced carcinogenesis in case of cervical cancer. So far, the role of non-genomic estrogen signals in cervical cancer, e.g. transmitted by the G protein-coupled estrogen receptor (GPER) remains to be rather elusive. Today’s knowledge on the role of GPER in cervical cancer is sparse and—to the best of our knowledge—GPER has not been investigated in context with clinicopathological parameters or prognosis of cervical cancer. Therefore, the current study investigated whether GPER is expressed in cervical cancer tissue. Further, GPER was correlated to clinicopathological parameters, tissue markers of cervical carcinogenesis and to patient overall and recurrence-free survival.
Materials and methods
Cervical cancer tissue was collected from 156 patients during surgery between 1993 and 2002. GPER immunostaining was performed on all the cases and correlated to clinicopathological data. More than half of all patients were diagnosed at advanced stage (FIGO II–IV 93/156; 59.6%) of disease. The large majority of patients presented with tumours of intermediate or high grade (G2–3 140/152, 92.1%). 22 cervical cancer-related deaths (22/156, 14.1%) were documented during the follow-up period.
Results
GPER was detected in various subcellular staining patterns. In 129/156 (82.7%) cases GPER was expressed in the tumour cell cytoplasm (GPERcyt). GPER immunopositivity at the cell membrane (GPERmem) was found in 114/156 (73.1%) cases. While co-occurrence of both membrane and cytoplasmic staining (GPERcyt + GPERmem) was detected in the majority of tissue samples (101/156; 64.7%), only few cases (14/156, 9.0%) were classified as not expressing GPER at all. GPERcyt was positively correlated with tumour grade. Statistical associations of GPER and both p16 and p53 were detected. Finally, immunopositivity of GPERcyt was predictive for favourable overall as well as recurrence-free survival in cervical cancer of early stage (FIGO I).
Conclusion
This retrospective study reports GPERcyt to be associated with improved overall and recurrence-free survival in early-stage cervical cancer. Further investigations are needed thus to determine whether this observation may be of clinical impact. Interestingly, Raloxifene—a GPER-activating selective estrogen receptor modulator—has recently been demonstrated to be preventive for cervical cancer relapse in mice. Whether this effect is only reliant on raloxifene blocking ERα or may also be related to activation of GPER remains to be determined.
Similar content being viewed by others
References
Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJ (2007) Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer 121(1):106–110. doi:10.1002/ijc.22678
Bigler LR, Tate Thigpen J, Blessing JA, Fiorica J, Monk BJ (2004) Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 14(5):871–874. doi:10.1111/j.1048-891X.2004.14523.x
Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B (2010) Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res 30(4):1341–1345
Chen YH, Huang LH, Chen TM (1996) Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 224(3):651–659. doi:10.1006/bbrc.1996.1080
Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF (2008) Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 68(23):9928–9934. doi:10.1158/0008-5472.CAN-08-2051
den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M et al (2015) Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci USA 112(25):E3255–E3264. doi:10.1073/pnas.1509322112
Dian D, Janni W, Kuhn C, Mayr D, Karsten U, Mylonas I et al (2009) Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 32(5):238–244. doi:10.1159/000209280
Dian D, Lenhard M, Mayr D, Heublein S, Karsten U, Goletz S et al (2013) Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol 28(2):239–244
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS et al (2007) Prevalence of HPV infection among females in the United States. JAMA 297(8):813–819. doi:10.1001/jama.297.8.813
Friese K, Kuhn C, Mahner S, Jeschke U, Heublein S (2016) Cytoplasmic GPER predicts excellent overall and progression free survival in early stage cervical cancer. Geburtshilfe Frauenheilkd 76(04):PC24. doi:10.1055/s-0036-1580661
Heublein S, Mayr D, Vrekoussis T, Friese K, Hofmann SS, Jeschke U et al (2013a) The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients. PloS One 8(8):e71791. doi:10.1371/journal.pone.0071791
Heublein S, Vrekoussis T, Kuhn C, Friese K, Makrigiannakis A, Mayr D et al (2013b) Inducers of G-protein coupled estrogen receptor (GPER) in endometriosis: potential implications for macrophages and follicle maturation. J Reprod Immunol 97(1):95–103. doi:10.1016/j.jri.2012.10.013
Heublein S, Mayr D, Friese K, Jarrin-Franco MC, Lenhard M, Mayerhofer A et al (2014) The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors. Int J Mol Sci 15(9):15161–15172. doi:10.3390/ijms150915161
Kedzia W, Gozdzicka-Jozefiak A, Kwasniewska A, Schmidt M, Miturski R, Spaczynski M (2000) Relationship between HPV infection of the cervix and blood serum levels of steroid hormones among pre- and postmenopausal women. Eur J Gynaecol Oncol 21(2):177–179
Kim CJ, Um SJ, Kim TY, Kim EJ, Park TC, Kim SJ et al (2000) Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer 10(2):157–164
Liang S, Chen Z, Jiang G, Zhou Y, Liu Q, Su Q et al (2017) Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals. Cancer Lett 386:12–23. doi:10.1016/j.canlet.2016.11.003
Lin J, Albers AE, Qin J, Kaufmann AM (2014) Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis. PloS One 9(9):e106384. doi:10.1371/journal.pone.0106384
Madkan VK, Cook-Norris RH, Steadman MC, Arora A, Mendoza N, Tyring SK (2007) The oncogenic potential of human papilloma viruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol 157(2):228–241. doi:10.1111/j.1365-2133.2007.07961.x
Mangiamele LA, Gomez JR, Curtis NJ, Thompson RR (2017) GPER/GPR30, a membrane estrogen receptor, is expressed in the brain and retina of a social fish (Carassius auratus) and colocalizes with isotocin. J Comp Neurol 525(2):252–270. doi:10.1002/cne.24056
Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A et al (2011) The association of hormonal contraceptive use and HPV prevalence. Int J Cancer 128(12):2962–2970. doi:10.1002/ijc.25628
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005a) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184. doi:10.1093/jnci/dji237
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005b) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072. doi:10.1200/JCO.2004.01.0454
Meyer MR, Rosemann T, Barton M, Prossnitz ER (2017) GPER mediates functional endothelial aging in renal arteries. Pharmacology 100(3–4):188–193. doi:10.1159/000478732
Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM et al (2002) Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case–control study. Lancet 359(9312):1085–1092. doi:10.1016/S0140-6736(02)08150-3
Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS et al (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study. Lancet 359(9312):1093–1101. doi:10.1016/S0140-6736(02)08151-5
Ramachandran B (2017) Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr Relat Cancer 24(4):R99–R108. doi:10.1530/ERC-16-0571
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140
Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20(2):207–225. doi:10.1016/j.bpobgyn.2005.10.007
Scholz C, Toth B, Barthell E, Mylonas I, Weissenbacher T, Friese K et al (2009) Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity. Histol Histopathol 24(4):467–471
Son J, Park JW, Lambert PF, Chung SH (2014) Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis 35(2):489–496. doi:10.1093/carcin/bgt350
Spurgeon ME, Chung SH, Lambert PF (2014) Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy. Am J Pathol 184(2):530–540. doi:10.1016/j.ajpath.2013.10.013
Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(2 Suppl 1):S2–S5. doi:10.1016/j.ygyno.2007.07.067
Stiasny A, Kuhn C, Mayr D, Alexiou C, Janko C, Wiest I et al (2016) Immunohistochemical evaluation of E6/E7 HPV oncoproteins staining in cervical cancer. Anticancer Res 36(6):3195–3198
Sun Q, Liang Y, Zhang T, Wang K, Yang X (2017) ER-alpha36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells. Biochem Biophys Res Commun. doi:10.1016/j.bbrc.2017.04.105
Zhang Q, Wu YZ, Zhang YM, Ji XH, Hao Q (2015) Activation of G-protein coupled estrogen receptor inhibits the proliferation of cervical cancer cells via sustained activation of ERK1/2. Cell Biochem Funct 33(3):134–142. doi:10.1002/cbf.3097
Acknowledgements
The authors thank Irmgard Wiest for her excellent technical assistance. We would further like to acknowledge Jutta Engel and Max Wiedemann for their help with collecting follow-up data from the Munich Cancer Registry. Studies on GPER were supported by a grant of the Friedrich-Baur-Stiftung to SH. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. This study has been presented as a poster on the yearly meeting of Bavarian Society of Gynaecology and Obstetrics (BGGF) in 2016. The abstract of the poster presented at this meeting has been published in Geburtshilfe Frauenheilkd 2016; 76-PC24 (Friese et al. 2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that no competing interests exist.
Rights and permissions
About this article
Cite this article
Friese, K., Kost, B., Vattai, A. et al. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. J Cancer Res Clin Oncol 144, 13–19 (2018). https://doi.org/10.1007/s00432-017-2510-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2510-7